The PLAC test is a simple blood test approved by the US FDA in all individuals above 18 years of age irrespective of family history. The PLAC test or the Lp-PLA2 test measures the activity of the enzyme called Lp-PLA2. It has been observed that individuals with normal cholesterol levels and higher levels of PLAC (Lp – PLA2) are at a greater risk of developing heart attack. Likewise, individuals with high cholesterol but low levels of PLAC (Lp-PLA2) are at a lower risk of developing heart attack and continue to lead a normal life. Hence the PLAC test acts as an independent marker of heart health which is imperative of your cholesterol levels. Heart attacks occur when the supply of oxygen rich blood is cut off to the heart. Over the years, when plaque (wax like substance that is made up of fat and cholesterol) accumulates in the arteries carrying blood to the heart, it results in heart disease. When plaque ruptures it leads to heart attack. LP-PLA2 is an enzyme that is involved in the formation of a plaque that is prone to rupture. Thus people with increased levels of blood level of Lp-PLA2 are at a greater risk of developing heart attack and stroke.
Global & National Quality Accreditations – CAP (USA) and NABL , Govt. of India.
Guaranteed error free diagnosis.
Bar Coded and automated process. No room for manual errors.
Specific normal range for Indian population built from 33 years of experience.
Sample collection from home/office.
Metropolis: Experience + Expertise
Over the past 3 decades we have earned the respect of doctors and patients. Today we conduct over 30 million tests annually with accuracy each year. Our repertoire extends over 4500 tests and over 100 different technologies. Our customer care is available round the clock for any queries that you may have.
Save tax on the Preventive health check-ups up to Rs. 5000, under section 80D of Income Tax Act, 1961
We are Metropolis - Your Pathology Specialist
Metropolis is one of the leading diagnostics companies in India, by revenue, as of March 31, 2018 (Source: Frost & Sullivan). With operations across India, Africa, South Asia and Middle East.
Our globally accredited clinical laboratories deliver millions of accurate and timely test results every year. We offer a comprehensive range of clinical laboratory tests and profiles which are used in prediction, early detection, diagnostic screening, confirmation and monitoring of diseases.
Delivering diagnostic services since 1980
Network of 100+ clinical labs & 1100+ patient touch points
Qualified team of phlebotomists for Home collection services
Certified NABL and CAP accredited labs
Wide range of 4000+ tests & profiles
Convenience of home collection service
Metropolis Healthcare Limited is proposing subject to applicable statutory or regulatory requirements, receipt of requisite approvals, market conditions and other considerations to undertake an initial public offering of its equity shares and has filed a draft red herring prospectus dated September 27, 2018 (“DRHP”) with the Securities and Exchange Board of India (“SEBI”). The DRHP is available on the website of the SEBI at www.sebi.gov.in, BSE Limited at www.bseindia.com, National Stock Exchange of India Limited at www.nseindia.com and the websites of Book Running Lead Managers at www.jmfl.com, www.credit-suisse.com, www.investmentbank.kotak.com, www.hdfcbank.com and www.goldmansachs.com. Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to same, please refer to the DRHP including the section “Risk Factors” of the DRHP. Potential investors should not rely on the DRHP filed with the SEBI for making any investment decision.